Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

2.9K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.9K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

2.8K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.8K
Disturbances in Heart Rhythm01:29

Disturbances in Heart Rhythm

5.5K
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
5.5K
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

598
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
598
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

1.7K
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
1.7K
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

1.2K
Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
1.2K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

The novel molecule porcine OSR1 up-regulated expression on porcine endothelial cell by human peripheral blood mononuclear cell activation.

Transplantation proceedings·2004
Same author

Screening and analysis of porcine endogenous retrovirus in Chinese Banna minipig inbred line.

Transplantation proceedings·2004
Same author

Study of renal function matching between Banna Minipig Inbred line and human.

Transplantation proceedings·2004
Same author

Induction of neuropeptide gene expression and blockade of retrograde transport in facial motor neurons following local peripheral nerve inflammation in severe combined immunodeficiency and BALB/C mice.

Neuroscience·2004
Same author

Utilization of treated swine wastewater for greenhouse tomato production.

Water science and technology : a journal of the International Association on Water Pollution Research·2004
Same author

Multistrange baryon production in Au-Au collisions at sqrt[s(NN)]=130 GeV.

Physical review letters·2004

相关实验视频

Updated: May 6, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.2K

在接受amiodarone治疗的患者中,用ibutilide对心房或的化学心脏转变.

K Glatter1, Y Yang, K Chatterjee

  • 1Cardiovascular Research Institute and Section of Cardiac Electrophysiology, University of California, San Francisco 94143-1354, USA.

Circulation
|February 24, 2001
PubMed
概括

结合伊布利德和阿米奥达龙的联合治疗有效地转化了心房失常症. 尽管QT延长,torsade de pointes是罕见的,这表明这种组合是一种有用的心脏转变方法.

更多相关视频

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.6K
Cox-Maze IV Procedure Concomitant with Valvular Surgery In Situs Inversus Dextrocardia: A Single-Center Experience in China
08:42

Cox-Maze IV Procedure Concomitant with Valvular Surgery In Situs Inversus Dextrocardia: A Single-Center Experience in China

Published on: February 11, 2022

3.8K

相关实验视频

Last Updated: May 6, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.2K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.6K
Cox-Maze IV Procedure Concomitant with Valvular Surgery In Situs Inversus Dextrocardia: A Single-Center Experience in China
08:42

Cox-Maze IV Procedure Concomitant with Valvular Surgery In Situs Inversus Dextrocardia: A Single-Center Experience in China

Published on: February 11, 2022

3.8K

科学领域:

  • 心脏病学 心脏病学
  • 电子生理学 电子生理学

背景情况:

  • 伊布提利德是一种用于心脏转变的III类抗心律失常剂,但具有torsade de pointes的风险.
  • 另一种抗心律失常药物阿米奥达龙可以延长QT间隔,但很少引起torsade de pointes.
  • 之前没有研究过ibutilide和amiodarone的同时使用.

研究的目的:

  • 评估结合ibutilide与amiodarone用于心脏转变的疗效和安全性.
  • 评估心房或的患者组合治疗的成功率.

主要方法:

  • 长期接受阿米奥达龙治疗的70名患者接受了选择性心脏转变.
  • 静脉注射伊布提利德 (2毫克) 被给予,如果需要,随后进行电动心脏转换.
  • 监测了QT间隔和左心室喷射率.

主要成果:

  • 伊布提利德转化了39%的心房动和54%的心房动病例.
  • 另外90%的非转换患者通过电疗成功进行了心脏转换.
  • 在ibutilide后,QT间隔显著延长 (371毫秒至479毫秒),有一例非持续的torsade de pointes (1.4%).

结论:

  • 结合伊布蒂利德和阿米奥达龙的联合治疗证明在心脏转移慢性心房动和动中具有实用性.
  • 观察到的torsade de pointes的低发病率表明这种组合治疗的可管理的安全性.